Selank

Selank is a synthetic heptapeptide developed in Russia for the treatment of generalized anxiety disorder (GAD). It is a Tuftsin analog with modifications for improved stability. Unlike benzodiazepines, it does not cause sedation or withdrawal. Mechanism involves modulation of GABA receptors and neurotrophic factors.

PubMed results: 68 · Human studies: 15 · Animal studies: 64

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

• Intranasal — standard range 300-600 mcg, 2-3 times daily

Unknown (low confidence)

• Anxiolytic effects without benzodiazepine-like sedation (Moderate clinical): Russian clinical research on this synthetic tuftsin analog has reported anxiolytic activity in generalized anxiety settings without the sedation or withdrawal profile associated with benzodiazepines.
• GABA receptor and neurotrophic factor modulation (Limited): Mechanistic studies suggest Selank modulates GABAergic signaling and expression of neurotrophic factors, providing a research rationale for its observed central nervous system effects.
• Cognitive and stress-response research interest (Limited): Preclinical and limited clinical work has explored effects on stress adaptation and cognitive performance alongside anxiolytic endpoints, though independent replication outside Russian literature remains limited.

• Nasal mucosal irritation (intranasal formulations) — Mild, Uncommon. When studied via intranasal delivery, local nasal irritation has been reported; published human adverse-event data remain sparse relative to Western trial standards.
• Limited documented systemic adverse effects — Mild, Not established. Available literature describes a generally favorable tolerability profile, but systematic long-term safety characterization in large international trials is not established.

• Pregnancy and lactation (research caution) (Theoretical / Preclinical): Adequate reproductive-toxicity and human pregnancy data are lacking for this investigational peptide; standard research practice excludes pregnant and lactating populations.
• Concurrent GABAergic or CNS-active drug research cautions (Theoretical / Preclinical): Given proposed GABA pathway modulation, concurrent use with sedatives or other CNS-active agents is approached cautiously in research settings due to theoretical interaction risk.

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water

• NCT05832060 — Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With Dyslexia (NA), status: UNKNOWN. Indications: Developmental Dyslexia
• NCT00464269 — Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures (PHASE3), status: COMPLETED. Indications: Epilepsy
• NCT01747200 — Effects of Transcranial Magnetic Stimulation on Object Recognition (NA), status: COMPLETED. Indications: Repetitive TMS (rTMS), Sham rTMS, Bilateral rTMS, Unilateral rTMS
• NCT04989088 — Neurofeedback Training for Dyslexia (NA), status: UNKNOWN. Indications: Dyslexia, Reading Problem
• NCT07196085 — Neural Mechanisms and Efficacy of Imagery Rescripting for Fear of Failure (NA), status: COMPLETED. Indications: Fear of Failure
• NCT00504881 — Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy (PHASE3), status: COMPLETED. Indications: Epilepsy
• NCT06151093 — The Effect of Balance Exercises on Cognitive Function (NA), status: COMPLETED. Indications: EEG Brain Oscillations, Balance Exercises
• NCT05411185 — The Study on Effects of Acute Exposure to High Altitude Hypoxia on Cognitive Function in Lowlanders, status: COMPLETED. Indications: Cognition
• NCT01770990 — Trial of Telephone-based Psychotherapy for Depression With and Without Adjunctive Supportive Mail (NA), status: COMPLETED. Indications: Depression
• NCT05076045 — Effects of PSAPs on Speech Processing (NA), status: COMPLETED. Indications: Hearing Loss, Age-Related